Indolent Non Follicular Lymphomas Prognostic Project
- Conditions
- Interventions
- First Posted Date
- 2016-09-19
- Last Posted Date
- 2024-06-28
- Lead Sponsor
- Fondazione Italiana Linfomi - ETS
- Target Recruit Count
- 370
- Registration Number
- NCT02904577
- Locations
- 🇮🇹
UO Oncoematologia Ospedale Umberto I, Pagani, Salerno, Italy
🇮🇹US Oncoematologia- Ospedale Valduce, Como, Italy
🇮🇹Ematologia Ospedale Madonna delle Grazie, Matera, Italy
Ledipasvir+Sofosbuvir and Sofosbuvir+Velpatasvir for Pts With Indolent Bcell Lymphoma Associated With HCV Infection
- Conditions
- Interventions
- First Posted Date
- 2016-07-19
- Last Posted Date
- 2023-03-31
- Lead Sponsor
- Fondazione Italiana Linfomi - ETS
- Target Recruit Count
- 40
- Registration Number
- NCT02836925
- Locations
- 🇮🇹
Ematologia - Policlinico Umberto I Università Sapienza, Roma, Italy
🇮🇹A.O. Spedali Civili, Brescia, BS, Italy
🇮🇹U.O. Ematologia AO di Padova, Padova, Italy
"MIRO" Molecularly Oriented Immuno-radio-therapy
- Conditions
- Interventions
- First Posted Date
- 2016-03-17
- Last Posted Date
- 2022-06-21
- Lead Sponsor
- Fondazione Italiana Linfomi - ETS
- Target Recruit Count
- 110
- Registration Number
- NCT02710643
- Locations
- 🇮🇹
Ospedale SS. Antonio e Biagio e Cesare Arrigo, Alessandria, AL, Italy
🇮🇹Area Vasta Romagna e IRST, Meldola (FC), Italy
🇮🇹Ematologia Azienda Ospedaliera Policlinico, Bari, BA, Italy
Phase II Study About Combination CHOP-21, Obinutuzumab and Ibrutinib in Untreated Young High Risk DLBCL Patients.
- First Posted Date
- 2016-02-01
- Last Posted Date
- 2017-03-20
- Lead Sponsor
- Fondazione Italiana Linfomi - ETS
- Target Recruit Count
- 1
- Registration Number
- NCT02670317
- Locations
- 🇮🇹
IRCCS Napoli Pascale, Napoli, Italy
🇮🇹Ospedale San Gerardo, Monza, Italy
🇮🇹Ospedale Maggiore della Carità, Novara, Italy
Bendamustine Plus Brentuximab Vedotin in HL and CD30+ PTCL in First Salvage Setting
- Conditions
- Interventions
- First Posted Date
- 2015-07-16
- Last Posted Date
- 2021-05-27
- Lead Sponsor
- Fondazione Italiana Linfomi - ETS
- Target Recruit Count
- 43
- Registration Number
- NCT02499627
- Locations
- 🇮🇹
Spedali Civili, Brescia, BS, Italy
🇮🇹AOU Città della Salute e della Scienza, Torino, TO, Italy
🇮🇹IRCCS Fondazione Pascale, Napoli, Italy
Study on the Role of Brentuximab Vedotin as Single Agent in the Treatment of Relapsed/Refractory CD30+ PTCL Patients
- First Posted Date
- 2015-07-14
- Last Posted Date
- 2022-03-22
- Lead Sponsor
- Fondazione Italiana Linfomi - ETS
- Target Recruit Count
- 25
- Registration Number
- NCT02497131
- Locations
- 🇮🇹
Ematologia e Trapianto IRCCS, Istituto Nazionale dei Tumori, Milano, Italy
🇮🇹SC Ematologia - Città della Salute e della Scienza, Torino, Italy
🇮🇹A.O. Universitaria S. Maria Della Misericordia Di Udine, Udine, Italy
GA101-miniCHOP Regimen for the Treatment of Elderly Unfit Patients With Diffuse Large B-cell Non-Hodgkin's Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2015-07-13
- Last Posted Date
- 2020-11-05
- Lead Sponsor
- Fondazione Italiana Linfomi - ETS
- Target Recruit Count
- 34
- Registration Number
- NCT02495454
- Locations
- 🇮🇹
Asmn-Irccs, Reggio Emilia, RE, Italy
🇮🇹Ematologia 1U - AO Città della Salute e della Scienza, Torino, TO, Italy
🇮🇹A.O. S. Maria di Terni, Terni, TR, Italy
A Study of SGN-35 (Brentuximab Vedotin) of Patients With Relapsed or Refractory PMLBCL
- Conditions
- Interventions
- First Posted Date
- 2015-04-22
- Last Posted Date
- 2017-06-26
- Lead Sponsor
- Fondazione Italiana Linfomi - ETS
- Target Recruit Count
- 15
- Registration Number
- NCT02423291
- Locations
- 🇮🇹
Divisione di Ematologia Azienda Ospedaliera "Bianchi Melacrino Morelli", Reggio Calabria, RC, Italy
🇮🇹Unità funzionale di Ematologia A.O.U. Careggi, Firenze, FI, Italy
🇮🇹Dip. Oncologia, Ematologia e Patologie dell'apparato respiratorio A.O.U. Policlinico di Modena, Modena, MO, Italy
Rituximab and Lenalidomide vs Rituximab Alone as Maintenance After R-chemoterapy for Relapsed/Refractory FL Patients
- First Posted Date
- 2015-03-18
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Fondazione Italiana Linfomi - ETS
- Target Recruit Count
- 128
- Registration Number
- NCT02390869
- Locations
- 🇮🇹
ASST Valle Olona - Ospedale di Circolo di Busto Arsizio, Busto Arsizio, Varese, Italy
🇮🇹AO Santa Croce e Carle, Cuneo, Italy
🇮🇹Ospedale C. e G. Mazzoni UOS Ematologia, Ascoli Piceno, Italy
Phase II Study With Ga101-DHAP as Induction Therapy in Relapsed/Refractory DLBCL Patients
- First Posted Date
- 2015-02-27
- Last Posted Date
- 2022-06-06
- Lead Sponsor
- Fondazione Italiana Linfomi - ETS
- Target Recruit Count
- 29
- Registration Number
- NCT02374424
- Locations
- 🇮🇹
Ospedale di Bolzano, Reparto di Ematologia & CTMO, Bolzano, Italy
🇮🇹Ematologia Policlinico San Matteo, Pavia, Italy
🇮🇹Policlinico Umberto I - Università "La Sapienza", Roma, Italy